Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium-103 or iodine-125

被引:3
|
作者
Shirvani, Shervin M.
Kudchadker, Rajat J. [2 ]
Bruno, Teresa L. [2 ]
Likhacheva, Anna
Swanson, David A. [3 ]
Frank, Steven J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 97, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
关键词
Postimplant dosimetry; Prostate brachytherapy; Prostate cancer; Foley catheter; Catheterization; URETHRAL STRICTURES; CANCER;
D O I
10.1016/j.brachy.2010.12.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE: Postoperative dosimetry is integral to quality assurance for prostate brachytherapy. Images on Day 0 are typically obtained with a contrast-filled urinary catheter in place for urethral dose calculations. However, expansion of the urethra and perhaps the prostate by the catheter may affect target coverage. We assessed. the effect of urinary catheterization on target dosimetry after implantation with palladium-103 ((103)Pd) or iodine-125 ((125)I) seeds. METHODS AND MATERIALS: Patients were 29 consecutive men with postimplant dosimetry calculated with and without a urinary catheter after brachytherapy seed implantation; 19 patients received (103)Pd seeds and 10 patients received (125)I seeds. In each case, 14-French caude tip urinary catheters were placed before implantation, and axial CT slices of the pelvis were obtained before and after catheter removal for postimplant dosimetry. Dosimetric parameters were measured and compared with paired Student's t tests. Trends were assessed by linear regression with the Pearson correlation coefficient. RESULTS: Removal of the urinary catheter significantly improved V(100) and D(90) for (103)Pd implants (mean +/- standard deviation (SD), 2.7% +/- 4.2%; range, -0.4% to 15%; p = 0.011 and mean +/- SD, 4.0% +/- 3.4%; range, -0.1% to 13.8%; p < 0.01, respectively). For (125)I implants, catheter removal improved D(90) (mean +/- SD, 1.5% +/- 1.8%; range, -1.3% to 4.2%; p = 0.027). For the (103)Pd group, the magnitude of change in V(100) correlated with prostate size (R(2) = 0.16) and source number (R(2) = 0.15). CONCLUSIONS: Urinary catheterization can artificially reduce target coverage after prostate implant brachytherapy. The patients undergoing (103)Pd implantation with smaller (<30 cm(3)) prostates and fewer (<90) sources are particularly susceptible to reduced D(90) and V(100) when a urinary catheter is present. (C) 2011 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:269 / 274
页数:6
相关论文
共 50 条
  • [21] Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy
    Elshaikh, MA
    Angermeier, K
    Ulchaker, JC
    Klein, EA
    Chidel, MA
    Mahoney, S
    Wilkinson, DA
    Reddy, CA
    Ciezki, JP
    UROLOGY, 2003, 61 (01) : 152 - 155
  • [22] Calibration Seed Sampling for Iodine-125 Prostate Brachytherapy
    Crowe, Scott
    Kairn, Tanya
    WORLD CONGRESS ON MEDICAL PHYSICS AND BIOMEDICAL ENGINEERING 2018, VOL 3, 2019, 68 (03): : 459 - 462
  • [23] INFLUENCE OF POSTIMPLANT DOSIMETRY TIME TO EVALUATION OF IODINE-125 IMPLANTATION RESULTS FOR PROSTATE CANCER BRACHYTHERAPY
    Jarusevicius, Laimonas
    Inciura, Arturas
    Juozaityte, Elona
    MEDICAL PHYSICS IN THE BALTIC STATES, 2012, : 90 - 90
  • [24] A comparison of the shielding effectiveness of silicone oil vitreous substitutes when used with Palladium-103 and Iodine-125 eye plaques
    Yang, You M.
    Chow, Phillip E.
    McCannel, Tara A.
    Lamb, James M.
    MEDICAL PHYSICS, 2019, 46 (02) : 1006 - 1011
  • [25] TRANSPERINEAL PALLADIUM-103 PROSTATE BRACHYTHERAPY - ANALYSIS OF MORBIDITY AND SEED MIGRATION
    NAG, S
    SCAPEROTH, DD
    BADALAMENT, R
    HALL, SA
    BURGERS, J
    UROLOGY, 1995, 45 (01) : 87 - 92
  • [26] Radiomic and dosiomic prediction of biochemical failure after Iodine-125 prostate brachytherapy
    Nakano, M.
    Ishiyama, H.
    Kawakami, S.
    Sekiguchi, A.
    Kainuma, T.
    Tsumura, H.
    Hashimoto, M.
    Hasegawa, T.
    Tanaka, Y.
    Katakura, T.
    Murakami, Y.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1595 - S1596
  • [27] A nalysis of immune status after iodine-125 permanent brachytherapy in prostate cancer
    Du, E.
    Wang, Lin
    Li, Chang-ying
    Zhang, Chang-wen
    Qu, Yan-chun
    Liu, Ran-lu
    Xu, Yong
    Yang, Kuo
    Zhang, Zhi-hong
    ONCOTARGETS AND THERAPY, 2017, 10 : 2561 - 2567
  • [28] A prediction model for biochemical failure after salvage Iodine-125 prostate brachytherapy
    Peters, M.
    van Zyp, J. R. N. Van der Voort
    Moerland, M. A.
    Hoekstra, C. J.
    Van de Pol, S.
    Westendorp, H.
    Maenhout, M.
    Kattevilder, R.
    Verkooijen, H. M.
    Van Rossum, P. S. N.
    Ahmed, H. U.
    Shah, T.
    Emberton, M.
    Van Vulpen, M.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S28 - S29
  • [29] Salvage iodine-125 brachytherapy for local prostate cancer recurrence after radiotherapy
    Celada, F.
    Chicas, R.
    Soler, A.
    Roldan, S.
    Candela, C.
    Gimeno, J.
    Tormo, A.
    Perez-Calatayud, J.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S679 - S679
  • [30] Prostatic length predicts functional outcomes after iodine-125 prostate brachytherapy
    Pal, Raj P.
    Bhatt, Jaimin R.
    Khan, Masood A.
    Duggleby, Stuart
    Camilleri, Philip
    Bell, C. Richard
    Elwell, Christine
    Kunkler, Roger B.
    BRACHYTHERAPY, 2011, 10 (02) : 107 - 116